Longhaul Covid19 - Revision history

Bosmana: /* References */

2020-09-01T14:24:34Z

‎References

Bosmana at 14:24, 1 September 2020

2020-09-01T14:24:14Z

Bosmana at 14:14, 1 September 2020

2020-09-01T14:14:01Z

Bosmana: Created page with "This page collects observations, interpretations, and consequences for action about Long-term COVID19 sequellae. Please observe the structure of the page, when you add your co..."

2020-09-01T13:38:23Z

Created page with "This page collects observations, interpretations, and consequences for action about Long-term COVID19 sequellae. Please observe the structure of the page, when you add your co..."

New page

This page collects observations, interpretations, and consequences for action about Long-term COVID19 sequellae. Please observe the structure of the page, when you add your content. Please use references where possible. Remember to find the relevant page. For example, if your observation is about [[transmission routes]], please use that page, instead of posting your content here.

=Long-haul COVID19=
==What is already known==
* Hospitalised COVID19 patients were assessed approximately 60 days after onset of the first COVID-19 symptom; at the time of the evaluation, only 18 (12.6%) were completely free of any COVID-19–related symptom, while 32% had 1 or 2 symptoms and 55% had 3 or more. Worsened quality of life was observed among 44.1% of patients. <Ref name="Carfi2020">Carfì, A., Bernabei, R., & Landi, F. (2020). Persistent Symptoms in Patients After Acute COVID-19. JAMA.</ref>

==Observations==

==Analysis and interpretation==

==Consequences for action==

=References=
</references>

← Older revision		Revision as of 14:24, 1 September 2020
Line 21:		Line 21:

	=References=		=References=
−	</~~references~~>	+	<references/>

@@ Line 8: / Line 8: @@
 * The emerging data and anecdotal evidence of long term recovery and persistent debilitating symptoms highlight the need for robust, standardised studies to assess the risk of and risk factors for consequences after COVID -19 infection. The ISARIC study aims to establish a longitudinal cohort of patients with COVID -19 post-discharge, to characterize the risk of long-term consequences and immune response over time in different populations globally. <ref name="ISARIC2020">Sigfrid, L., Jesudason, E., Lim, W. S., Rello, J., Amuasi, J. H., Drake, T. M., ... & Kildal, A. What is the recovery rate and risk of long-term consequences from COVID-19?-A harmonised, global observational study protocol.</ref>
 ==Observations==
 ==Analysis and interpretation==
 ==Consequences for action==

@@ Line 3: / Line 3: @@
 =Long-haul COVID19=
 ==What is already known==
-* Hospitalised COVID19 patients were assessed approximately 60 days after onset of the first COVID-19 symptom; at the time of the evaluation, only 18 (12.6%) were completely free of any COVID-19–related symptom, while 32% had 1 or 2 symptoms and 55% had 3 or more. Worsened quality of life was observed among 44.1% of patients. <Ref name="Carfi2020">Carfì, A., Bernabei, R., & Landi, F. (2020). Persistent Symptoms in Patients After Acute COVID-19. JAMA.</ref>
+* Among 143 COVID19 patients that were followed-up after discharge, only 18 (12.6%) were completely free of any COVID-19–related symptom when assessed on average 60.3 days after disease onset. Of those who were still symptomatic, 32% had 1 or 2 symptoms and 55% had 3 or more. The most common persistent symptoms were fatigue and dyspnoea. Worsened quality of life was observed among 44.1% of patients. <Ref name="Carfi2020">Carfì, A., Bernabei, R., & Landi, F. (2020). Persistent Symptoms in Patients After Acute COVID-19. JAMA.</ref>
 ==Observations==